HCWB Stock Soars Pre-Market On Positive Research Results For CAR-T Cell Therapy

• HCW Biologics stated that CAR-T cells manufactured with HCW9206 were significantly superior to those manufactured with standard methods.
• The company said that CAR-Ts produced with its reagent are highly enriched in long-lived T memory stem cells.
• HCW Biologics added that these CAR-Ts also displayed potent activity across distinct disease experimental models, namely, HIV-1 or B-cell leukemia.

HCW Biologics Inc. (HCWB) shares soared more than 56% in Monday’s pre-market trade after the company announced positive research results for its CAR-T cell therapy.

HCW Biologics stated that HCW9206, its proprietary, commercial-stage multi-cytokine fusion protein reagent, provides a new approach to generate CAR-T cells for immunotherapy with increased function at a cost-effective price.

Retail sentiment on Stocktwits around HCW Biologics trended in the ‘bullish’ territory with message volumes at ‘high’ levels.

HCW9206 CAR-Ts Outperform Standard Methods, Says Company

HCW Biologics stated that CAR-T cells manufactured with HCW9206 were significantly superior to those manufactured with standard methods.

The company said that CAR-Ts produced using its reagent are highly enriched in long-lived T-memory stem cells. HCW Biologics added that these CAR-Ts also displayed potent activity across distinct disease experimental models, namely, HIV-1 or B-cell leukemia.

“Based on experimental models, HCW9206 has shown improvement in functional activities and persistence of CAR-Ts following adoptive transfer, a goal the industry has been trying to achieve for the last decade,” said HCW Biologics CEO, Dr. Hing C. Wong.

The company stated that in its study, HCW9206 helped generate long-lasting duoCAR-T cells that showed strong HIV suppression in humanized mouse models using T cells from people living with HIV. The approach could extend CAR-T therapy durability and support efforts toward a functional HIV cure, it added.

Why Are CAR-T Cells Important?

CAR-T cells represent a new way to treat cancer using the patient’s own immune system. These cells genetically modify a patient’s T cells so they can recognize and attack specific cancer cells, reducing damage to healthy tissue compared with traditional treatments.

Additionally, once CAR-T cells are modified and infused into a patient’s body, they multiply and continue to fight cancer.

HCWB stock is down 47% year-to-date and 96% over the past 12 months. The Vanguard Extended Market Index Fund ETF Shares (VXF) is up 20% over the past 12 months.

Also See: SOC Stock Rises Pre-Market After Energy Secretary Order Restarts Sable’s California Oil Pipeline

For updates and corrections, email newsroom[at]stocktwits[dot]com.